Gemina Laboratories Ltd
CNSX:GLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its Industry Average (4.3), the stock would be worth CA$-0.29 (817% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.6 | CA$0.04 |
0%
|
| Industry Average | 4.3 | CA$-0.29 |
-817%
|
| Country Average | 2.7 | CA$-0.18 |
-547%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
G
|
Gemina Laboratories Ltd
CNSX:GLAB
|
3.1m CAD | -0.6 | -1 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
308.8B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 1 319.4 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
101.6B ZAR | 1.1 | 10.5 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.5B USD | 1 973.5 | 38 690 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
55.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.1B CHF | 0 | 0 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.8B USD | 53.7 | -3 284.6 | |
| US |
|
Coupang Inc
F:788
|
32.4B EUR | 8.1 | 179.2 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.8B ZAR | 1 | 6.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
Gemina Laboratories Ltd
Glance View
Gemina Laboratories Ltd. (Gemina) is a Canada-based biotechnology company. Gemina operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. It is engaged in biosensor and diagnostic services with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Gemina's technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Gemina is focused on infectious respiratory diseases and the recovery from them. It has developed a first-generation technology (the Generation 1 Technology), which it has included within an initial demonstration product namely: a point-of-care lateral flow assay to test whether a person is infected with COVID-19 (the Legio-XTM COVID Rapid Antigen Test).
